Pascal Vranckx

71.2k total citations · 10 hit papers
164 papers, 16.2k citations indexed

About

Pascal Vranckx is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Pascal Vranckx has authored 164 papers receiving a total of 16.2k indexed citations (citations by other indexed papers that have themselves been cited), including 132 papers in Cardiology and Cardiovascular Medicine, 84 papers in Surgery and 33 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Pascal Vranckx's work include Coronary Interventions and Diagnostics (60 papers), Antiplatelet Therapy and Cardiovascular Diseases (53 papers) and Acute Myocardial Infarction Research (50 papers). Pascal Vranckx is often cited by papers focused on Coronary Interventions and Diagnostics (60 papers), Antiplatelet Therapy and Cardiovascular Diseases (53 papers) and Acute Myocardial Infarction Research (50 papers). Pascal Vranckx collaborates with scholars based in Belgium, Netherlands and United States. Pascal Vranckx's co-authors include Roxana Mehran, Donald E. Cutlip, Patrick W. Serruys, Stephan Windecker, Mitchell W. Krucoff, Philippe Gabríel Steg, Marie‐Angèle Morel, Marco Valgimigli, Gerrit‐Anne van Es and Eugène McFadden and has published in prestigious journals such as The Lancet, Circulation and Journal of the American College of Cardiology.

In The Last Decade

Pascal Vranckx

153 papers receiving 15.9k citations

Hit Papers

Clinical End Points in Co... 2007 2026 2013 2019 2007 2011 2011 2011 2018 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Clinical End Points in Coronary Stent Trials
    2007 4.2k citations Donald E. Cutlip, Stephan Windecker et al. Circulation profile →
  2. Standardized Bleeding Definitions for Cardiovascular Clinical Trials
    2011 2.9k citations Roxana Mehran, Deepak L. Bhatt et al. Circulation profile →
  3. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium
    2011 897 citations Donald E. Cutlip, A. Pieter Kappetein et al. European Heart Journal profile →
  4. Standardized Endpoint Definitions for Transcatheter Aortic Valve Implantation Clinical Trials
    2011 540 citations Donald E. Cutlip, A. Pieter Kappetein et al. profile →
  5. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document
    2018 514 citations Héctor M. García‐García, Eugène McFadden et al. Circulation profile →
  6. Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting
    2012 441 citations Marco Valgimigli, Gianluca Campo et al. Circulation profile →
  7. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial
    2019 383 citations Pascal Vranckx, Marco Valgimigli et al. profile →
  8. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
    2018 371 citations Sigrun Halvorsen, Marco Valgimigli et al. profile →
  9. Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 2: Endpoint Definitions
    2015 356 citations Gregg W. Stone, A. Pieter Kappetein et al. profile →
  10. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
    2017 332 citations Sigrun Halvorsen, Marco Valgimigli et al. Revista Española de Cardiología (English Edition) profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Pascal Vranckx 13.8k 9.4k 3.5k 2.3k 1.9k 164 16.2k
Franz‐Josef Neumann 12.8k 0.9× 7.1k 0.8× 2.7k 0.8× 2.5k 1.1× 2.6k 1.4× 285 16.5k
C. Michael Gibson 11.8k 0.9× 6.8k 0.7× 3.9k 1.1× 1.2k 0.5× 1.0k 0.6× 220 15.1k
Eugenia Nikolsky 9.3k 0.7× 4.9k 0.5× 2.7k 0.8× 3.2k 1.4× 1.7k 0.9× 131 14.4k
Marco Roffi 12.1k 0.9× 6.5k 0.7× 3.6k 1.0× 4.7k 2.0× 1.6k 0.9× 271 16.6k
Richard W. Smalling 11.4k 0.8× 6.3k 0.7× 4.2k 1.2× 2.8k 1.2× 2.9k 1.6× 257 16.2k
Marc Cohen 13.0k 0.9× 6.2k 0.7× 4.0k 1.1× 1.3k 0.6× 856 0.5× 287 16.2k
Dariusz Dudek 8.0k 0.6× 4.5k 0.5× 2.2k 0.6× 1.8k 0.8× 883 0.5× 360 10.0k
David Antoniucci 9.4k 0.7× 5.5k 0.6× 3.3k 0.9× 830 0.4× 904 0.5× 231 10.5k
Joseph F. Sabik 11.3k 0.8× 8.3k 0.9× 1.4k 0.4× 4.0k 1.7× 3.1k 1.7× 267 14.3k
Marie‐Claude Morice 8.5k 0.6× 7.7k 0.8× 4.0k 1.1× 2.0k 0.8× 727 0.4× 184 10.6k

Countries citing papers authored by Pascal Vranckx

Since Specialization
Citations

This map shows the geographic impact of Pascal Vranckx's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pascal Vranckx with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pascal Vranckx more than expected).

Fields of papers citing papers by Pascal Vranckx

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pascal Vranckx. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pascal Vranckx. The network helps show where Pascal Vranckx may publish in the future.

Co-authorship network of co-authors of Pascal Vranckx

This figure shows the co-authorship network connecting the top 25 collaborators of Pascal Vranckx. A scholar is included among the top collaborators of Pascal Vranckx based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pascal Vranckx. Pascal Vranckx is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zito, Andrea, Antonio Landi, Enrico Frigoli, et al.. (2025). In-hospital platelet count dynamics in patients with acute coronary syndrome. Revista Española de Cardiología (English Edition). 79(3). 257–269.
2.
Grand, Johannes, Pascal Vranckx, & Sean van Diepen. (2025). DAPT-SHOCK-AMI: does faster and more complete platelet inhibition translate to improved clinical outcomes?. European Heart Journal Acute Cardiovascular Care. 14(9). 562–564.
3.
4.
Halvorsen, Sigrun, Pascal Vranckx, & Sean van Diepen. (2024). Should renin–angiotensin system inhibitors be stopped or not before non-cardiac surgery?. European Heart Journal Acute Cardiovascular Care. 13(9). 670–671. 1 indexed citations
5.
Vranckx, Pascal, David A. Morrow, Sean van Diepen, & Frederik H. Verbrugge. (2024). As we reflect on the year 2023…….. European Heart Journal Acute Cardiovascular Care. 13(1). 1–1. 1 indexed citations
6.
7.
Vranckx, Pascal, David A. Morrow, Sean van Diepen, & Frederik H. Verbrugge. (2024). Resilience and renewal: charting the future of cardiovascular care in a changing world. European Heart Journal Acute Cardiovascular Care. 13(10). 683–684. 1 indexed citations
8.
Galea, Roberto, Nicolas Méneveau, Federico De Marco, et al.. (2023). One-Year Outcomes After Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: A Prespecified Analysis of the SWISS-APERO Randomized Clinical Trial. Circulation. 149(6). 484–486. 15 indexed citations
9.
Vranckx, Pascal & Sean van Diepen. (2023). BIOVASC trial in perspective: complete revascularization strategies in patients presenting with acute coronary syndromes and multi-vessel coronary disease. European Heart Journal Acute Cardiovascular Care. 12(4). 217–218. 1 indexed citations
10.
Landi, Antonio, Nuccia Morici, Pascal Vranckx, et al.. (2023). Edoxaban and/or colchicine in outpatients with COVID-19: rationale and design of the CONVINCE trial. Journal of Cardiovascular Medicine. 24(12). 920–930. 1 indexed citations
11.
Chieffo, Alaide, Dariusz Dudek, Christian Hassager, et al.. (2021). Joint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices. European Heart Journal Acute Cardiovascular Care. 10(5). 570–583. 51 indexed citations
12.
Chieffo, Alaide, Dariusz Dudek, Christian Hassager, et al.. (2021). Joint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices. EuroIntervention. 17(4). e274–e286. 25 indexed citations
13.
Capodanno, Davide, Marco Di Maio, Antonio Greco, et al.. (2020). Safety and Efficacy of Double Antithrombotic Therapy With Non–Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis. Journal of the American Heart Association. 9(16). e017212–e017212. 56 indexed citations
14.
Dockx, Kim, Bert Avau, Emmy De Buck, Pascal Vranckx, & Philippe Vandekerckhove. (2019). Physical manoeuvers as a preventive intervention to manage vasovagal syncope: A systematic review. PLoS ONE. 14(2). e0212012–e0212012. 8 indexed citations
15.
Spitzer, Ernest, Eugène McFadden, Pascal Vranckx, et al.. (2018). Defining Staged Procedures for Percutaneous Coronary Intervention Trials. JACC: Cardiovascular Interventions. 11(9). 823–832. 11 indexed citations
16.
García‐García, Héctor M., Eugène McFadden, Andrew Farb, et al.. (2018). Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Circulation. 137(24). 2635–2650. 514 indexed citations breakdown →
17.
Wall, Benjamin T., Marlou L. Dirks, Lex B. Verdijk, et al.. (2012). Neuromuscular electrical stimulation increases muscle protein synthesis in elderly type 2 diabetic men. American Journal of Physiology-Endocrinology and Metabolism. 303(5). E614–E623. 70 indexed citations
18.
Valgimigli, Marco, Gianluca Campo, Monia Monti, et al.. (2012). Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting. Circulation. 125(16). 2015–2026. 441 indexed citations breakdown →
19.
Tubaro, Marco, Nicolas Danchin, Gerasimos Filippatos, et al.. (2011). The ESC textbook of acute and intensive cardiac care. Oxford University Press eBooks. 2 indexed citations
20.
Cutlip, Donald E., Stephan Windecker, Roxana Mehran, et al.. (2007). Clinical End Points in Coronary Stent Trials. Circulation. 115(17). 2344–2351. 4204 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Franz‐Josef Neumann Breakdown of academic impact, for papers by C. Michael Gibson Breakdown of academic impact, for papers by Eugenia Nikolsky Breakdown of academic impact, for papers by Marco Roffi Breakdown of academic impact, for papers by Richard W. Smalling Breakdown of academic impact, for papers by Marc Cohen Breakdown of academic impact, for papers by Dariusz Dudek Breakdown of academic impact, for papers by David Antoniucci Breakdown of academic impact, for papers by Joseph F. Sabik Breakdown of academic impact, for papers by Marie‐Claude Morice
Rankless by CCL
2026